Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EPS (Weighted Average and Diluted) (2020 - 2025)

Tg Therapeutics (TGTX) has 6 years of EPS (Weighted Average and Diluted) data on record, last reported at $0.14 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 6.67% year-over-year to $0.14; the TTM value through Dec 2025 reached $2.77, up 1878.57%, while the annual FY2025 figure was $2.77, 1746.67% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $0.14 in Q4 2025 per TGTX's latest filing, down from $2.43 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.43 in Q3 2025 and bottomed at -$0.71 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.07, with a median of -$0.17 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 97.26% in 2024, then skyrocketed 12050.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.71 in 2021, then rose by 19.84% to -$0.57 in 2022, then skyrocketed by 96.49% to -$0.02 in 2023, then skyrocketed by 850.0% to $0.15 in 2024, then fell by 6.67% to $0.14 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $0.14 in Q4 2025, $2.43 in Q3 2025, and $0.17 in Q2 2025.